

Thank you for your interest in *Case Studies in Immuno-Oncology* conducted by the Institute for Clinical Immuno-Oncology (ICLIO), an institute of the Association of Community Cancer Centers (ACCC).

To be considered for this opportunity, your cancer program must meet the following criteria:

- Be a current ACCC Cancer Program Member. \*
- Have already established—or be in the initial stages of implementing—an immuno-oncology (I-O) program, and be willing to discuss your I-O program with ACCC and ICLIO.
- □ Have plans to expand your immuno-oncology program over the next two years.
- Assign a point of contact (POC) to coordinate with the ICLIO team.
- □ Have a commitment from at least one clinician to submit two de-identified patient cases to ACCC and ICLIO.
- □ Have a commitment from at least 5-10 key cancer care professionals who will be present for the "Case Studies in I-O" tumor board discussion.
- Provide permission to ACCC and ICLIO to publish key findings and outcomes on their respective websites, as well as in white papers, social media posts, webinars, blogs, newsletters, and live conferences.

Please email the application to us by Friday, September 29, 2017, to Brissan Guardado (bguardado@accc-cancer.org).

\*This program was formerly known as ICLIO Grand Rounds.

## ACCC Cancer Program Name:


Name and emails of individual(s) completing this application and email(s):

| What is your role on the multidisciplinary cancer care team? |
|--|
| o Cancer program administrator                               |
| o Medical director   |
| <ul> <li>Medical oncologist</li> </ul>                       |
| o Nurse/nurse navigator                                      |

- o Pharmacist
- o Cancer registry manager/coordinator
- o Other:\_\_\_\_\_

## Information about your immuno-oncology program:

- 1) On average, how many patients does your program treat with immuno-oncologic agents each year (checkpoint inhibitors [anti-PD-1s, anti CTLA-4s]/vaccines/other immunotherapies used to treat patients with cancer)?
  - **□** 0 − 25
  - **□** 26 50
  - □ 51 75
  - **□** 76 100
  - **>**100
- 2) On a scale from 1 to 5, where 1 is "not at all operational" and 5 is "fully operational," how would you rate your immuno-oncology program?



4) What day(s) of the week would you prefer to schedule this program?

- □ Monday
- □ Tuesday
- Wednesday
- □ Thursday
- Friday
- 5) Do you prefer morning or afternoon?
  - Morning
  - □ Afternoon
- 6) Approximately what percent of immunotherapy drugs are prescribed at your institution for the following tumor types? (Total must equal 100%.)

| Non-Small Cell Lung Cancer | % |
|----------------------------|---|
| Melanoma                   | % |
| Bladder Cancer             | % |
| Head & Neck Cancer         | % |
| Hodgkin Lymphoma           | % |
| Kidney Cancer              | % |
| Other                      | % |

- 7) From a clinical-case and educational perspective, which tumor types would your institution be most interested in discussing during the program?
  - Non-Small Cell Lung Cancer
  - Melanoma
  - Bladder Cancer
  - Head & Neck Cancer
  - Hodgkin Lymphoma
  - □ Kidney Cancer
  - □ Other (please specify)
- 9) Please list any other immuno-oncology topics that are of potential interest to your institution:

10) Please provide the name and email address of the clinician who will provide the deidentified patient cases for the tumor board discussion.

Thank you for your interest in the ICLIO "Case Studies in I-O" program. You will be notified of a decision in three - four weeks.

ICLIO is made possible by a charitable donation from Bristol-Myers Squibb and supported by an educational grant from Merck & Co., Inc.

